April 28 (Reuters) - Pharmaxis Ltd PXS.AX :
* PXS CANCER DRUG READY TO COMMENCE PHASE 2 STUDIES Q4 2020
* PROGRESSING TO PHASE 2 STUDY OF ORAL ANTI‐FIBROTIC PAN‐LYSYL OXIDASE INHIBITOR TO TREAT MYELOFIBROSIS
April 28 (Reuters) - Pharmaxis Ltd PXS.AX :
* PXS CANCER DRUG READY TO COMMENCE PHASE 2 STUDIES Q4 2020
* PROGRESSING TO PHASE 2 STUDY OF ORAL ANTI‐FIBROTIC PAN‐LYSYL OXIDASE INHIBITOR TO TREAT MYELOFIBROSIS